Cargando…
Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reacti...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756544/ https://www.ncbi.nlm.nih.gov/pubmed/32935877 http://dx.doi.org/10.1111/trf.16065 |
_version_ | 1783626566011453440 |
---|---|
author | Wendel, Silvano Kutner, Jose Mauro Machado, Rafael Fontão‐Wendel, Rita Bub, Carolina Fachini, Roberta Yokoyama, Ana Candelaria, Gabriela Sakashita, Araci Achkar, Ruth Hamerschlak, Nelson Scuracchio, Patricia Amaral, Marcelo Dal Ben, Mirian Araujo, Danielle Soares, Camila Camargo, Anamaria Kallás, Esper Durigon, Edison Reis, Luiz Fernando Rizzo, Luiz Vicente |
author_facet | Wendel, Silvano Kutner, Jose Mauro Machado, Rafael Fontão‐Wendel, Rita Bub, Carolina Fachini, Roberta Yokoyama, Ana Candelaria, Gabriela Sakashita, Araci Achkar, Ruth Hamerschlak, Nelson Scuracchio, Patricia Amaral, Marcelo Dal Ben, Mirian Araujo, Danielle Soares, Camila Camargo, Anamaria Kallás, Esper Durigon, Edison Reis, Luiz Fernando Rizzo, Luiz Vicente |
author_sort | Wendel, Silvano |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT‐PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and absence of symptoms for ≥14 days plus (a) age (18‐60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T‐lymphotropic virus‐1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT‐PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect–based virus neutralization test neutralizing antibody) and anti–nucleocapsid protein SARS‐CoV‐2 IgM, IgG, and IgA enzyme‐linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT‐PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT‐PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT‐PCR –ve, and 25/69 RT‐PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT‐PCR –ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a “golden period” for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT‐PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti–nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody. |
format | Online Article Text |
id | pubmed-7756544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77565442020-12-28 Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program Wendel, Silvano Kutner, Jose Mauro Machado, Rafael Fontão‐Wendel, Rita Bub, Carolina Fachini, Roberta Yokoyama, Ana Candelaria, Gabriela Sakashita, Araci Achkar, Ruth Hamerschlak, Nelson Scuracchio, Patricia Amaral, Marcelo Dal Ben, Mirian Araujo, Danielle Soares, Camila Camargo, Anamaria Kallás, Esper Durigon, Edison Reis, Luiz Fernando Rizzo, Luiz Vicente Transfusion Donor Infectious Disease Testing BACKGROUND: Coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. METHODS AND MATERIALS: Mild/moderate COVID‐19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT‐PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and absence of symptoms for ≥14 days plus (a) age (18‐60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T‐lymphotropic virus‐1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT‐PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect–based virus neutralization test neutralizing antibody) and anti–nucleocapsid protein SARS‐CoV‐2 IgM, IgG, and IgA enzyme‐linked immunosorbent assays. RESULTS: Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT‐PCR was negative on swab (77.0%) or blood (88.4%; P = .46). Final definition of RT‐PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT‐PCR –ve, and 25/69 RT‐PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT‐PCR –ve with neutralizing antibody ≥160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P < .05), probably denoting a “golden period” for CCP collection (≤28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. CONCLUSIONS: RT‐PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti–nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody. John Wiley & Sons, Inc. 2020-09-16 2020-12 /pmc/articles/PMC7756544/ /pubmed/32935877 http://dx.doi.org/10.1111/trf.16065 Text en © 2020 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Donor Infectious Disease Testing Wendel, Silvano Kutner, Jose Mauro Machado, Rafael Fontão‐Wendel, Rita Bub, Carolina Fachini, Roberta Yokoyama, Ana Candelaria, Gabriela Sakashita, Araci Achkar, Ruth Hamerschlak, Nelson Scuracchio, Patricia Amaral, Marcelo Dal Ben, Mirian Araujo, Danielle Soares, Camila Camargo, Anamaria Kallás, Esper Durigon, Edison Reis, Luiz Fernando Rizzo, Luiz Vicente Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title | Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title_full | Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title_fullStr | Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title_full_unstemmed | Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title_short | Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
title_sort | screening for sars‐cov‐2 antibodies in convalescent plasma in brazil: preliminary lessons from a voluntary convalescent donor program |
topic | Donor Infectious Disease Testing |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756544/ https://www.ncbi.nlm.nih.gov/pubmed/32935877 http://dx.doi.org/10.1111/trf.16065 |
work_keys_str_mv | AT wendelsilvano screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT kutnerjosemauro screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT machadorafael screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT fontaowendelrita screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT bubcarolina screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT fachiniroberta screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT yokoyamaana screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT candelariagabriela screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT sakashitaaraci screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT achkarruth screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT hamerschlaknelson screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT scuracchiopatricia screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT amaralmarcelo screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT dalbenmirian screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT araujodanielle screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT soarescamila screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT camargoanamaria screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT kallasesper screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT durigonedison screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT reisluizfernando screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram AT rizzoluizvicente screeningforsarscov2antibodiesinconvalescentplasmainbrazilpreliminarylessonsfromavoluntaryconvalescentdonorprogram |